Quantcast

Latest R207910 Stories

2011-11-30 10:50:15

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections. DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin,...

2009-06-17 08:15:00

SEATTLE, June 17 /PRNewswire/ -- When: Wednesday, June 17, 2009, 10:30am Eastern (9:30am Central; 8:30am Mountain; 7:30am Pacific) Dial-in: 1-877-879-6184 (toll-free) 1-719-325-4759 (local access) Conference Title: TB Alliance/Tibotec Briefing Participant passcode: 2895940 Where: Pacific Health Summit Bell Harbor International Conference Center Pacific Board Room Seattle,...

2009-06-17 07:00:00

Collaboration will focus on the development of TMC207 and the discovery of new drugs to treat tuberculosis SEATTLE, June 17 /PRNewswire/ -- A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, has been announced today at the Pacific Health Summit in response to the urgent need to accelerate the discovery and development of new drugs to...

2009-06-03 16:00:00

Clinical Activity Of TMC207 shows ATP-Synthase is a Viable Target for treatment of TB MECHELEN, Belgium, June 3 /PRNewswire/ -- Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today. TMC207 is being developed by Tibotec BVBA. The data show that the addition of TMC207 for eight weeks to a 5-drug background...

2008-09-15 09:00:11

Tuberculosis drug shows promise against latent bacteria WASHINGTON, Sept. 12 (Xinhua) -- A new study has shown that an investigational drug R207910, currently in clinical trials against multi-drug resistant tuberculosis strains, is quite effective at killing latent bacteria, a report said on Friday. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease, researchers from Johnson & Johnson reported in the Sept. 12 issue...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related